Table 1 Breast cancer intrinsic subtypes with prevalent immuno-histochemical profiles and options of treatment [3]
From: Molecular characterization and targeted therapeutic approaches in breast cancer
Intrinsic subtype | cDNA microarrays | IHC | Treatment |
|---|---|---|---|
Luminal A | The highest expression of the ER α gene, GATA-binding protein 3, X-box-binding protein 1, trefoil factor 3, hepatocyte nuclear factor 3 α, and estrogen-regulated LIV-1 | ER- and/or PR-positive HER2-negative Ki-67 < 14% | Endocrine therapy (chemotherapy for selected patients) |
Luminal B | Low to moderate expression of the luminal-specific genes, including the ER cluster | ER- and/or PR-positive HER2-negative with Ki-67 ≥ 14% | Endocrine therapy ± chemotherapy |
ER- and/or PR-positive HER2-positive with any Ki-67 | Chemotherapy + anti-HER2 therapy + endocrine therapy | ||
HER2-enriched | High expression of several genes in the ERBB2 amplicon at 17q22.24, including ERBB2 and GRB7 | ER- and PR-negative HER2-positive | Chemotherapy + anti-HER2 therapy |
Basal-like | High expression of keratins 5 and 17, laminin, and fatty acid-binding protein 7 | ER- and PR-negative HER2-negative | Chemotherapy |